Brief: Ultragenyx And Mereo Biopharma Announce New Phase 2 Data From Phase 2/3 Orbit Study Demonstrating Sustained Reductions In Fracture Rates Following Treatment With Setrusumab (Ux143) In Patients With Osteogenesis Imperfecta (Oi)
11/06/2024 23:23
Mereo Biopharma Group PLC MAH0y.F :
* ULTRAGENYX AND MEREO BIOPHARMA ANNOUNCE NEW PHASE 2 DATA
FROM
PHASE 2/3 ORBIT STUDY DEMONSTRATING SUSTAINED REDUCTIONS IN
FRACTURE RATES FOLLOWING TREATMENT WITH SETRUSUMAB (UX143) IN
PATIENTS WITH OSTEOGENESIS IMPERFECTA (OI)
* MEREO BIOPHARMA GROUP PLC -AS OF DATA CUT-OFF, THERE WERE
NO
TREATMENT-RELATED SERIOUS ADVERSE EVENTS OBSERVED IN STUDY
Source text for Eikon: ID:nGNXbHGgdD
Further company coverage: MAH0y.F
Recent news on Mereo BioPharma
See all newsBrief: Sentynl Therapeutics And Mereo Biopharma Announce Option And License Agreement For Alvelestat In Alpha-1 Antitrypsin Deficiency-Associated Lung Disease
UK's Mereo BioPharma Q2 loss narrows on lower R&D spending
Brief: Mereo BioPharma Q2 Operating Income USD -7.03 Million
Brief: Mereo BioPharma Q1 Net Income USD -6.719 Million
Brief: Mereo BioPharma FY Revenue USD 500 Thousand Vs. IBES Estimate USD 520 Thousand